These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26652787)

  • 1. [The TECOS, EXAMINE and SAVOR studies--how do they differ and what are their outcomes?].
    Špinar J; Špinarová L; Vítovec J
    Vnitr Lek; 2015 Nov; 61(11):976-83. PubMed ID: 26652787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.
    Schernthaner G; Cahn A; Raz I
    Diabetes Care; 2016 Aug; 39 Suppl 2():S210-8. PubMed ID: 27440835
    [No Abstract]   [Full Text] [Related]  

  • 3. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
    Clifton P
    Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on the 'gliptins'.
    Drug Ther Bull; 2016 Dec; 54(12):138-141. PubMed ID: 27979881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective.
    Hirshberg B; Katz A
    Curr Diab Rep; 2015 Nov; 15(11):87. PubMed ID: 26370698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New antihyperglycemic drugs. Examination of cardiovascular outcomes with alogliptin versus standard of care (EXAMINE) and saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI 53)].
    Gallwitz B; Nitschmann S
    Internist (Berl); 2014 Jul; 55(7):859-62. PubMed ID: 24969610
    [No Abstract]   [Full Text] [Related]  

  • 8. Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.
    Kaneko M; Narukawa M
    Ann Pharmacother; 2017 Jul; 51(7):570-576. PubMed ID: 28622738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
    Simó R; Hernández C
    Rev Esp Cardiol (Engl Ed); 2016 Nov; 69(11):1005-1007. PubMed ID: 27659856
    [No Abstract]   [Full Text] [Related]  

  • 10. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
    Scheen AJ
    Diabetes Metab; 2012 Apr; 38(2):89-101. PubMed ID: 22197148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Saxagliptin, alogliptin, and cardiovascular outcomes.
    Standl E
    N Engl J Med; 2014 Jan; 370(5):483. PubMed ID: 24476445
    [No Abstract]   [Full Text] [Related]  

  • 12. DPP-4 inhibitors: what may be the clinical differentiators?
    Gerich J
    Diabetes Res Clin Pract; 2010 Nov; 90(2):131-40. PubMed ID: 20708812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct glucose-lowering properties in good responders treated with sitagliptin and alogliptin.
    Kutoh E; Hirate M; Wada A
    Int J Clin Pract; 2015 Nov; 69(11):1296-302. PubMed ID: 26194442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gliptins - do they increase cardiovascular risk or benefit?
    Doggrell SA; Dimmitt SB
    Expert Opin Drug Saf; 2014 May; 13(5):675-80. PubMed ID: 24684173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
    Scheen AJ; Charpentier G; Ostgren CJ; Hellqvist A; Gause-Nilsson I
    Diabetes Metab Res Rev; 2010 Oct; 26(7):540-9. PubMed ID: 20824678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment.
    Davis TM
    Diabetes Obes Metab; 2014 Oct; 16(10):891-9. PubMed ID: 24684351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
    Mannucci E; Monami M
    Adv Ther; 2017 Jan; 34(1):1-40. PubMed ID: 27844335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study.
    Leibowitz G; Cahn A; Bhatt DL; Hirshberg B; Mosenzon O; Wei C; Jermendy G; Sheu WH; Sendon JL; Im K; Braunwald E; Scirica BM; Raz I
    Diabetes Obes Metab; 2015 May; 17(5):487-94. PubMed ID: 25656169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase-4 inhibitors and cardiovascular safety.
    Davis TM
    Med J Aust; 2014 May; 200(8):450-1. PubMed ID: 24794596
    [No Abstract]   [Full Text] [Related]  

  • 20. Lessons from SAVOR and EXAMINE: some important answers, but many open questions.
    Schernthaner G; Sattar N
    J Diabetes Complications; 2014; 28(4):430-3. PubMed ID: 24713467
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.